You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR ERLOTINIB HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for ERLOTINIB HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00130520 ↗ Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer Completed Genentech, Inc. Phase 2 2005-06-01 The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).
New Combination NCT00130520 ↗ Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer Completed University of Arizona Phase 2 2005-06-01 The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).
New Combination NCT02353741 ↗ Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC Terminated Xinqiao Hospital of Chongqing Phase 2 2015-04-01 This single-arm phase II study aims to study the efficacy of a possible first line treatment that combines epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) with concurrent thoracic radiation therapy for stage IV non-small cell lung cancer (NSCLC) with active EGFR mutation, as well as assessing PFS, OS, tumor response, etc. to verify that this new combinational therapy can benefit short-term and long-term survival of the patients with advanced NSCLC.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for ERLOTINIB HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00026338 ↗ Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer Completed NCIC Clinical Trials Group Phase 3 2001-10-29 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and biological therapy may kill more tumor cells. It is not yet known if gemcitabine is more effective with or without erlotinib in treating pancreatic cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with and without erlotinib in treating patients who have unresectable locally advanced or metastatic pancreatic cancer.
NCT00030446 ↗ Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCIC Clinical Trials Group Phase 2 2002-01-10 RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with carboplatin may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining erlotinib and carboplatin in treating patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer.
NCT00030485 ↗ Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer Completed NCIC Clinical Trials Group Phase 2 2002-01-01 RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to determine the effectiveness of erlotinib in treating patients who have locally advanced and/or metastatic endometrial cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ERLOTINIB HYDROCHLORIDE

Condition Name

Condition Name for ERLOTINIB HYDROCHLORIDE
Intervention Trials
Non-Small Cell Lung Cancer 117
Lung Cancer 66
Carcinoma, Non-Small-Cell Lung 52
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ERLOTINIB HYDROCHLORIDE
Intervention Trials
Carcinoma, Non-Small-Cell Lung 410
Lung Neoplasms 348
Carcinoma 89
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ERLOTINIB HYDROCHLORIDE

Trials by Country

Trials by Country for ERLOTINIB HYDROCHLORIDE
Location Trials
Italy 222
Germany 97
United Kingdom 93
Japan 78
Brazil 78
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ERLOTINIB HYDROCHLORIDE
Location Trials
California 168
Texas 149
New York 134
Florida 115
Illinois 109
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ERLOTINIB HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for ERLOTINIB HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 20
Phase 3 89
Phase 2/Phase 3 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ERLOTINIB HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 495
Terminated 129
Unknown status 82
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ERLOTINIB HYDROCHLORIDE

Sponsor Name

Sponsor Name for ERLOTINIB HYDROCHLORIDE
Sponsor Trials
National Cancer Institute (NCI) 170
Genentech, Inc. 110
Hoffmann-La Roche 72
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ERLOTINIB HYDROCHLORIDE
Sponsor Trials
Other 846
Industry 562
NIH 171
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.